Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PRVB | Common Stock | Options Exercise | $125K | +50K | +1.95% | $2.50* | 2.62M | Feb 10, 2023 | Direct | |
transaction | PRVB | Common Stock | Sale | -$506K | -50K | -1.91% | $10.11 | 2.57M | Feb 10, 2023 | Direct | F1, F2 |
transaction | PRVB | Common Stock | Options Exercise | $64.6K | +25.8K | +1.01% | $2.50* | 2.6M | Feb 13, 2023 | Direct | |
transaction | PRVB | Common Stock | Sale | -$259K | -25.8K | -1% | $10.04 | 2.57M | Feb 13, 2023 | Direct | F1, F3 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PRVB | Stock Option (right to buy) | Options Exercise | $0 | -50K | -9.66% | $0.00 | 468K | Feb 10, 2023 | Common Stock | 50K | $2.50 | Direct | F4 |
transaction | PRVB | Stock Option (right to buy) | Options Exercise | $0 | -25.8K | -5.53% | $0.00 | 442K | Feb 13, 2023 | Common Stock | 25.8K | $2.50 | Direct | F4 |
Id | Content |
---|---|
F1 | The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2022. |
F2 | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.28 per share, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
F3 | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.42 per share, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. |
F4 | The option is fully vested. |